Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Lenvatinib and GEMOX for Biliary Tract Cancer
NCT05036798Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in biliary tract cancer (BTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05036798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036798.